Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 8/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | CASP9 | P55211 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TGM2 | P21980 | 3/20 | 0.38 |
| ▸ | CES1 | P23141 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indigotindisulfonate SCHEMBL2727226 | 1.00 | CA12 (0.50) | CA12CA1CA2CA9CASP3 | |
| Indigotindisulfonate SCHEMBL2732840 | 1.00 | CA12 (0.50) | CA12CA1CA2CA9CASP3 | |
| Indigotindisulfonate SCHEMBL29387846 | 1.00 | CA12 (0.50) | CA12CA1CA2CA9CASP3 | |
| Indigotindisulfonate SCHEMBL186297 | 1.00 | CA12 (0.50) | CA12CA1CA2CA9CASP3 | |
| Indigotindisulfonate SCHEMBL3652418 | 0.98 | CA12 (0.49) | CA12CA1CA2CA9CASP3 | |
| Indigotindisulfonate SCHEMBL3680504 | 0.98 | CA12 (0.49) | CA12CA1CA2CA9CASP3 | |
| Indigotindisulfonate SCHEMBL29694234 | 0.98 | CA12 (0.49) | CA12CA1CA2CA9CASP3 | |
| Indigotindisulfonate SCHEMBL186296 | 0.98 | CA12 (0.49) | CA12CA1CA2CA9CASP3 | |
| Indigotindisulfonate SCHEMBL9107944 | 0.98 | CA12 (0.49) | CA12CA1CA2CA9CASP3 | |
| Indigotindisulfonate SCHEMBL3960977 | 0.96 | CA12 (0.47) | CA12CA1CA2CA9CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9839591-B2 | Anionic dye or brightener bearing an ammonium or phosphonium counterion, dye composition comprising them and process for dyeing keratin fibres using these dyes | L'OREAL (FR) | 2017-12-12 | — | — | US | disclosed |
| US-9839591-B2 | Anionic dye or brightener bearing an ammonium or phosphonium counterion, dye composition comprising them and process for dyeing keratin fibres using these dyes | L'OREAL (FR) | 2017-12-12 | — | — | US | disclosed |
| US-20170229738-A1 | ELECTROLYTE FOR NONAQUEOUS SECONDARY BATTERY AND NONAQUEOUS SECONDARY BATTERY USING THE SAME | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2017-08-10 | — | — | US | disclosed |
| US-20170187060-A1 | INEXPENSIVE METAL-FREE ORGANIC REDOX FLOW BATTERY (ORBAT) FOR GRID-SCALE STORAGE | U.S. DEPARTMENT OF ENERGY | 2017-06-29 | — | — | US | disclosed |
| EP-3182501-A1 | ELECTROLYTE FOR NONAQUEOUS SECONDARY CELL AND NONAQUEOUS SECONDARY CELL USING SAME | National Institute of Advanced Industrial Science and Technology (JP) | 2017-06-21 | — | — | EP | disclosed |
| WO-2017093866-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF INDIGO CARMINE | DISHMAN PHARMACEUTICALS AND CHEMICALS LIMITED (IN) | 2017-06-08 | — | — | WO | disclosed |
| US-9670524-B2 | Test elements for determining an analyte concentration that include correction information for at least one interfering variable | ROCHE DIABETES CARE, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9614245-B2 | Inexpensive metal-free organic redox flow battery (ORBAT) for grid-scale storage | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2017-04-04 | — | — | US | disclosed |
| US-20170073499-A1 | LATEX COMPRISING COLORANT AND METHODS OF MAKING THE SAME | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2017-03-16 | — | — | US | disclosed |
| US-9580578-B2 | Latex comprising colorant and methods of making the same | XEROX CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| WO-2007130982-A2 | AQUEOUS ANTISEPTIC SOLUTION AND COMPATIBLE ANIONIC DYE FOR STAINING SKIN | ENTURIA, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| US-20070253909-A1 | Aqueous Antiseptic Solution and Compatible Cationic Dye for Staining Skin | MEDI-FLEX, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254854-A1 | Aqueous Antiseptic Solution and Compatible Anionic Dye for Staining Skin | MEDI-FLEX, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070249012-A1 | Microbial Detection and Quantification | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070186808-A1 | CYAN INK FOR INK-JET RECORDING | BROTHER KOGYO KABUSHIKI KAISHA (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070092579-A1 | Medical Products and Parenteral Formulations | BAXTER HEALTHCARE S.A. (CH) | 2007-04-26 | — | — | US | disclosed |
| US-20070048608-A1 | Redox-active polymers and their applications | BROWN UNIVERSITY | 2007-03-01 | — | — | US | disclosed |
| US-20070031976-A1 | Oxygen Indicator for Use in Medical Products | BAXTER INTERNATIONAL INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070029001-A1 | Multiple Chamber Container | BAXTER HEALTHCARE S.A. (CH) | 2007-02-08 | — | — | US | disclosed |
| US-20070010573-A1 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070253909-A1 | Aqueous Antiseptic Solution and Compatible Cationic Dye for Staining Skin | CUTA, POLR1C, TYR | CA12 122/4885CA1 637/4885CA2 190/4885 |
| US-20070092579-A1 | Medical Products and Parenteral Formulations | PROC, SLC5A6, PNLIP | CA12 1021/4885CA1 2191/4885CA2 875/4885 |
| US-20070254854-A1 | Aqueous Antiseptic Solution and Compatible Anionic Dye for Staining Skin | CUTA, IK, POLR1C | CA12 89/4885CA1 907/4885CA2 199/4885 |
| US-20070010573-A1 | Methods and compositions for treating amyloid-related diseases | APP, PSEN1, PSEN2 | CA12 998/4885CA1 582/4885CA2 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.